Pharmacodynamics of PEG-IFN alpha-2a in HIV/HCV co-infected patients: Implications for treatment outcomes

BACKGROUND & AIMS: The pharmacokinetics and pharmacodynamics of pegylated-interferon-α-2a (PEG-IFN) have not been described in HCV/HIV co-infected patients. We sought to estimate the pharmacokinetics and pharmacodynamics of PEG-IFN and determine whether these parameters predict treatment outcome...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Dahari, Harel, Affonso de Araujo, Evaldo S., Haagmans, Bart L., Layden, Thomas J., Cotler, Scott J., Barone, Antonio A., Neumann, Avidan U.
Formato: Artigo
Idioma:Inglês
Publicado: 2010
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2956745/
https://ncbi.nlm.nih.gov/pubmed/20561702
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jhep.2010.03.019
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares